Minimal residual disease monitoring in B-lineage acute lymphoblastic leukemia using flow cytometry. Guidelines of the Russian-Belarusian multicenter group for pediatric acute leukemia studies-Reference-Cited by-同舟云学术

Minimal residual disease monitoring in B-lineage acute lymphoblastic leukemia using flow cytometry. Guidelines of the Russian-Belarusian multicenter group for pediatric acute leukemia studies

Published:2023-10-03 Issue:3 Volume:22 Page:199-209
ISSN:2414-9314
Container-title:Pediatric Hematology/Oncology and Immunopathology
language:
Short-container-title:Voprosy gematologii/onkologii i immunopatologii v pediatrii

Author:

Popov A. M.¹^ORCID,Mikhailova E. V.¹^ORCID,Verzhbitskaya T. Yu.²^ORCID,Movchan L. V.³,Permikin Zh. V.²,Shman T. V.³,Karachunskiy A. I.¹^ORCID,Novichkova G. A.¹^ORCID

Affiliation:

1. The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

2. Regional Children's Clinical Hospital No.1

3. The Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

Abstract

Multicolor flow cytometry is now routinely used in laboratory practice for minimal residual disease (MRD) monitoring in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This article describes the methodology of MRD detection in BCP-ALL using flow cytometry as recommended by the Russian-Belarusian multicenter group for pediatric acute leukemia studies. This wellharmonized approach includes recommendations for the choice of monoclonal antibodies, sample preparation, cytometer setup, flow cytometry data analysis and interpretation as well as for reporting. These guidelines allow application of multicolor flow cytometry for MRD monitoring in BCP-ALL in children and adults both in local laboratories and in multicenter settings in prospective clinical trials.

Publisher

Fund Doctors, Innovations, Science for Children

Subject

Oncology,Hematology,Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Reference41 articles.

1. DiGiuseppe J.A., Wood B.L. Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma. Cytometry B Clin Cytom 2019; 96 (4): 256–65.

2. Chen X., Wood B.L. How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis? Best Pract Res Clin Haematol 2017; 30 (3): 237–48.

3. Van Dongen J.J., van der Velden V.H., Bruggemann M., Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 2015; 125 (26): 3996–4009.

4. Bruggemann M., Schrauder A., Raff T., Pfeifer H., Dworzak M., Ottmann O.G., et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia 2010; 24 (3): 521–35.

5. Keeney M., Wood B.L., Hedley B.D., DiGiuseppe J.A., Stetler-Stevenson M., Paietta E., et al. A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters. Cytometry B Clin Cytom 2018; 94 (2): 239–49.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of blinatumomab in children with de novo Ph-negative B-lineage acute lymphoblastic leukemia and slow clearance of minimal residual disease;Pediatric Hematology/Oncology and Immunopathology;2024-04-16

2. Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non‐high‐risk acute lymphoblastic leukemia treated according to the ALL‐MB 2008 protocol;Cancer Medicine;2024-04

3. Flow cytometric and cytomorphological definition of remission achievement in children with B-lineage acute lymphoblastic leukemia;Pediatric Hematology/Oncology and Immunopathology;2023-12-20

4. Guidelines for the use of flow cell sorting in diagnosis and monitoring of acute leukemia;Pediatric Hematology/Oncology and Immunopathology;2023-12-20